Author: Oannes Biotech
-
In a groundbreaking development, a team of scientists have discovered a new class of antibiotics using artificial intelligence, marking the first such breakthrough in over six decades. This momentous achievement stems from the recent publication of the paper titled “Discovery of a Structural Class of Antibiotics with Explainable Deep Learning.” The findings promise to be…
-
A Strategic Roadmap to Harness the Power of Artificial Intelligence in Medicines Regulation In a bold leap towards innovation, the European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMAs) have laid out a comprehensive AI workplan that charts the course for the integration of artificial intelligence in medicines regulation until 2028. This strategic…
-
In a strategic move that is set to reshape the landscape of the biopharmaceutical industry, Pfizer has announced its monumental $43 billion acquisition of Seagen. This landmark deal marks a significant step forward, propelling the company into new realms of innovation and therapeutic development. Background Pfizer, headquartered in New York, has long been a major…
-
In a groundbreaking move to advance cancer therapeutics, AstraZeneca, a global pharmaceutical giant, has recently entered into a strategic collaboration with Absci, a leading synthetic biology company. The deal, valued at an impressive $247 million, aims to harness the power of innovative antibody design to revolutionize cancer treatment. The Partnership The collaboration between AstraZeneca and…
-
Groundbreaking Gene-Editing Therapy Receives Green Light, Signaling a New Era in Sickle Cell Treatment Date: 12 December 2023 Introduction: In a landmark decision, the U.S. Food and Drug Administration (FDA) has granted approval to Vertex Pharmaceuticals and CRISPR Therapeutics for CASGEVY™ (exagamglogene autotemcel), a pioneering gene-editing therapy designed for the treatment of Sickle Cell Disease…
-
MHRA Approves CASGEVY™ for Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia, Marking a Milestone in Precision Medicine Date: 7 December 2023 Introduction: In a historic move that signals a new era in medical innovation, Vertex Pharmaceuticals and CRISPR Therapeutics have received authorization from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for the…